In the premarket trading session, Pluristem Therapeutics Inc. (PSTI) stock has surged by 13.94% to the price of $5.15 at the time of writing. PSTI stock closed the previous session at $4.52 gaining 1.57%. The PSTI stock volume traded today at 0.22 million shares. PSTI stock slumped by -58.26% in the past year while in the past week, the shares jumped by 4.39%. Pluristem Therapeutics Incis currently valued in the market at $144.46 million and has 31.74 million outstanding shares.
About Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. is a bio-therapeutics company that focuses on finding, designing, developing, and commercializing therapeutic products and treatments in order to cure and treat the unmet needs of certain diseases. The bio-therapeutics company along with its subsidiary Pluristem Ltd. specifically manufactures cell therapeutic products for the treatment of various ischemic, autoimmune disorders, inflammatory and hematologic conditions and disorders.
What kind of cell-therapies does Pluristem produce?
The company produces these cell therapy products which are placental expanded (PLX) based. Pluristem also has a Phase III clinical trial of PLX-PAD cells for the treatment of critical limb ischemia (CLI) for patients that are not fit and suitable for revascularization. This treatment will also help in the recovery after surgery for hip fracture, and acute radiation syndrome (ARS). Furthermore, PLX-PAD cells can also be therapy for peripheral and cardiovascular, and orthopedic diseases.
Expansive list of commercialization agreement for clinical trials
The company has made many license and commercialization agreements in the past for conducting clinical trials and commercialization of its cell therapeutic products. This includes treatment CLI and intermittent claudication in South Korea
For evaluating the potential of PLX cell therapies in preventing and treating medical conditions that take place during outer space missions, Pluristem has collaborated with NASA’s Ames Research Center. Along with NASA, PSTI stock has also collaborated with BCRT and BCAT to expand its clinical operations and research work; a joint project was launched for treatment and therapy of inflammatory as well as respiratory complications that are formed due to COVID-19 virus– PLX cells were evaluated to check their regenerative efficacy for treatment of these complications.
Announcing the positive result of the PLX-R18 hematology program
Today, 29th April 2021, Pluristem Therapeutics has announced that the phase I study of the innovative hematology program has delivered positive results. The study uses PLX-R18 – in humans -which is the first of its kind. To recover from the incomplete hematopoietic recovery following hematopoietic cell transplantation, Pluristemhas created PLX-R18 cells which are in Phase I clinical trial. PLX-R18 are also being researched and evaluated for the treatment of ARS. PLX-R18’s efficacy and safety was tested in the dose-escalation through intramuscular injections.
Why PLX-R18 cell therapy is a deal-maker for PSTI stock?
The study found out that PLX-R18 supports the blood cell lineage’s recovery, allowing assistance in the regenerative properties of hematopoietic cells. This is an important result because the complications with patients undergoing HCT like poor graft functioning can be life-threatening. Current treatments are not that effective to satisfy blood count and patients still face recurring infections which require more blood transfusions.
The PLX-R18 is the first candidate product which is manufactured by using 3D bioreactor system and the serum-free proprietary media of Pluristem.